Served as a panel member and writer for the American Association for the Study of Liver Diseases (AASLD) for the management of hepatitis C and also for nonalcoholic steatohepatitis. He is the only physician to serve on both panels.
Listed among “America’s Top Doctors” and “Best Doctors in America”.
Dr. Charlton has particular expertise in the diagnosis, treatment and management of nonalcoholic fatty liver disease (nonalcoholic steatohepatitis) and viral hepatitis.
Dr. Charlton has served as president of the International Liver Transplant Society.
Published more than 200 manuscripts, and is a lead investigator for national and international clinical trials in viral hepatitis and nonalcoholic fatty liver disease.
Over 10 years of specialized experience in MCM on ARS with
BARDA, NIH, FDA and DOD
Former Branch Chief, BARDA
Enzychem Lifesciences Corporation
is a Global New Drug Development Company that was founded on the most advanced life sciences and technologies of medicinal chemistry in July 1999. With its Global New Drug R&D center located in KAIST in Daejeon and its two GMP manufacturing plants in Seoul, it has since been developing and producing APIs and functional health foods, and developing global new drugs as the leader of the field.